Psychedelic research company MindMed is breaking new ground in the human brain and on the public markets. The psychedelic medicine completed a reverse takeover on the Canadian NEO exchange that made MindMed one of the first publicly traded psychedelic research companies. Cannabis reporter Chloe Aiello sat down with MindMed co-CEO and founder JR Rahn.